Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs.

Trial Profile

Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2017 Results of a pooled analysis from 093-045 and 093-046 trials presented at the 71st Annual Meeting of the American Epilepsy Society
    • 05 Dec 2017 Results of a post-hoc analysis of data pooled from 093-045 and 093-046 trials assessing cognitive adverse events presented at the 71st Annual Meeting of the American Epilepsy Society
    • 05 Dec 2017 Results of a post-hoc analysis of data pooled from 093-045 and 093-046 trials assessing psychiatric adverse events presented at the 71st Annual Meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top